Recent Updates
Recently added Catalysts
AKBA Positive Sentiment

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

Thursday, June 27, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Akebia Therapeutics announced that CEO John Butler will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on July 15, 2024. The presentation will focus on updates regarding the commercial launch of Vafseo (vadadustat) Tablets. A webcast of the presentation will be available for 30 days on Akebia's website.
Price reaction · baseline $0.9247 (2024-06-26 close) · hit after-hours · clean, no other AKBA news in the window
day 0 close
+7%
day 1 · peak
+10.3%
day 3
+3.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Akebia is actively engaging with the investor community.
  • The presentation will provide updates on the commercial launch of Vafseo.
  • Participation in a notable conference highlights Akebia's commitment to kidney health.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1%
120-day peak, hindsight
Typical move
8%
average across 4 past catalysts
Lead asset
ferric
Phase 3 · Anemia of Chronic Kidney Disease

Full Press Release Details

CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in the H.C. Wainwright 3 rd Annual Kidney Virtual Conference on Monday, July 15, 2024 . Mr. Butler will present at 9:30 a.m. ET to provide updates on the progress of commercial launch activities for Vafseo® (vadadustat) Tablets.
A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.
About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release.
Akebia Therapeutics Contact Mercedes Carrasco [email protected]

Frequently Asked Questions

When will Akebia present at the conference?

Akebia will present at the H.C. Wainwright Kidney Virtual Conference on July 15, 2024.

Who is presenting for Akebia Therapeutics?

John Butler, the CEO of Akebia Therapeutics, will present at the conference.

What will be discussed during the presentation?

The presentation will provide updates on the commercial launch activities for Vafseo.

How can I access the presentation?

The presentation can be accessed via Akebia's website for 30 days after the conference.

ShareAdd on Google
Tags: AKBA Viatris Investor Conferences Healthcare Akebia Therapeutics H.C. Wainwright Kidney Conference Vafseo vadadustat
Last updated: Jun 27, 2024

Biotech snapshot

Cash runway
$156M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ferricPhase 3
Anemia of Chronic Kidney Disease →

Catalyst track record

+1%
best trade around AKBA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AKBA.

See every catalyst's timing & PoA →